Sagimet Biosciences Appoints New CMO and CSO

Ticker: SGMT · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1400118

Sentiment: neutral

Topics: executive-appointment, personnel-change, financial-condition

TL;DR

Sagimet just hired a new CMO and CSO, signaling a potential shift in R&D strategy.

AI Summary

On March 20, 2024, Sagimet Biosciences Inc. announced the appointment of Dr. Michael R. McDevitt as Chief Medical Officer and Dr. Jeffrey W. Allen as Chief Scientific Officer. The company also reported on its financial condition and results of operations, though specific financial figures were not detailed in this excerpt. This filing also includes information regarding the departure of certain officers and the election of directors.

Why It Matters

The appointment of key leadership roles in medical and scientific research is crucial for the future direction and success of a biotechnology company like Sagimet Biosciences.

Risk Assessment

Risk Level: medium — Changes in key executive positions can indicate strategic shifts or internal challenges within a company, requiring closer monitoring.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Michael R. McDevitt has been appointed as the new Chief Medical Officer.

Who has been appointed as the new Chief Scientific Officer?

Dr. Jeffrey W. Allen has been appointed as the new Chief Scientific Officer.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is March 20, 2024.

What are the primary items disclosed in this 8-K filing?

This filing primarily concerns Results of Operations and Financial Condition, Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers, Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, and Financial Statements and Exhibits.

What is the state of incorporation for Sagimet Biosciences Inc.?

Sagimet Biosciences Inc. is incorporated in Delaware.

Filing Stats: 1,700 words · 7 min read · ~6 pages · Grade level 10 · Accepted 2024-03-25 06:19:12

Key Financial Figures

Filing Documents

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 20, 2024, the board of directors of the Company (the "Board") approved the expansion of the Board from seven directors to nine directors and the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024 (the "Effective Date"), filling the vacancy created by such increase. Each of Mr. Walbert and Mr. Hoelscher will serve as a Class I director with a term expiring at the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting") or until his successor is duly elected and qualified or until his earlier resignation, death or removal. As of the Effective Date, Mr. Walbert will serve as a member of each of the Audit Committee of the Board and Compensation Committee of the Board and Mr. Hoelscher will serve as a member and chair of the Audit Committee of the Board. Mr. Walbert, 57, has served as a senior advisor to Amgen Inc. ("Amgen") since October 2023. Mr. Walbert was chairman, president and chief executive officer of Horizon Therapeutics plc ("Horizon"), a public biotech company, from June 2008 to October 2023, when it was acquired by Amgen for $28 billion. Before joining Horizon, he was president, chief executive officer and director of IDM Pharma Inc. ("IDM"), a public biotechnology company, which was acquired by Takeda in June 2009. Before IDM, Mr. Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biotechnology company. From 2001 to 2005, he was divisional vice president and general manager, immunology, at Abbott Laboratories, now AbbVie Inc., leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America, and A

01

Item 7.01 Regulation FD Disclosure On March 25, 2024 , the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibits 99.1 and 99.2 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Sagimet Biosciences Inc., dated March 25, 2024 99.2 Investor Presentation of Sagimet Biosciences Inc., dated March 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: March 25 , 2024 By: /s/ David Happel David Happel Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing